Kymera Therapeutics (KYMR) EPS (Basic) (2019 - 2026)
Kymera Therapeutics (KYMR) reported EPS (Basic) of -$0.71 for Q1 2026, up 13.41% year-over-year from -$0.63 in Q1 2025, and up 27.55% quarter-over-quarter from -$0.98 in Q4 2025.
Kymera Therapeutics (KYMR) EPS (Basic) (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has 8 years of EPS (Basic) data on file, last reported at -$0.71 in Q1 2026.
- EPS (Basic) for Q1 2026 came in at -$0.71, up 13.41% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.58 (down 15.11% YoY), and the FY2025 annual result was -$3.69, down 23.83% from the prior year.
- EPS (Basic) rose to -$0.71 in Q1 2026 per KYMR's latest filing, from -$0.98 in the prior quarter.
- Over five years, EPS (Basic) peaked at -$0.25 in Q4 2023 and troughed at -$0.98 in Q4 2025.
- A 5-year average of -$0.75 and a median of -$0.78 in 2022 frame the typical range for EPS (Basic).
- The sharpest annual moves came in 2023 and 2024: EPS (Basic) soared 57.63% in 2023, then slumped 256.0% in 2024.
- A 5-year view of EPS (Basic) shows it stood at -$0.59 in 2022, then soared by 57.63% to -$0.25 in 2023, then tumbled by 256.0% to -$0.89 in 2024, then declined by 10.11% to -$0.98 in 2025, then gained by 27.55% to -$0.71 in 2026.
- Business Quant data shows KYMR's EPS (Basic) at -$0.71 in Q1 2026, -$0.98 in Q4 2025, and -$0.94 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 0.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.06 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.06 |
| 10 | Kymera Therapeutics | 8.84 Bn | 8.19 Bn | - | -0.71 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.71 |
| Dec 31, 2025 | -0.98 |
| Sep 30, 2025 | -0.94 |
| Jun 30, 2025 | -0.95 |
| Mar 31, 2025 | -0.82 |
| Dec 31, 2024 | -0.89 |
| Sep 30, 2024 | -0.82 |
| Jun 30, 2024 | -0.58 |
| Mar 31, 2024 | -0.69 |
| Dec 31, 2023 | -0.25 |
| Sep 30, 2023 | -0.90 |
| Jun 30, 2023 | -0.67 |
| Mar 31, 2023 | -0.70 |
| Dec 31, 2022 | -0.59 |
| Sep 30, 2022 | -0.79 |
| Jun 30, 2022 | -0.78 |
| Mar 31, 2022 | -0.71 |
| Dec 31, 2021 | -0.67 |
| Sep 30, 2021 | -0.56 |
| Jun 30, 2021 | -0.55 |